We have previously developed a novel adenovirus vector (Adv) that targeted tumor tissues/vasculatures after systemic administration. The surface of this Adv is conjugated with CGKRK tumor homing peptide by the cross-linking reaction of polyethyleneglycol (PEG). In this study, we showed that the condition of PEG modification was important to minimize the gene expression in normal tissues after systemic treatment. When Adv was modified only with PEG-linked CGKRK, its luciferase expression was enhanced even in the liver tissue, as well as the tumor tissue. However, in the reaction with the mixture of non-cross-linking PEG and PEG-linked CGKRK, we found out that the best modification could suppress its gene expression in the liver, without losi...
With the reason that systemically administered adenovirus (Ad) is rapidly extinguished by innate/ada...
The targeting of gene transfer at the cell-entry level is one of the most attractive challenges in v...
ABSTRACT: Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunog...
The aim of this study was to change adenovirus tropism by chemical modification of the fiber knobs w...
Despite adenovirus (Ad) vector's numerous advantages for cancer gene therapy, such as high abili...
Due to the fundamental progress in elucidating the molecular mechanisms of human diseases and the ar...
Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intra...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases t...
Adenovirus (Ad) is a potential vehicle for cancer gene therapy. However, cells that express low leve...
Oncolytic adenoviruses (Ad) that selectively replicate in cancer cells are emerging as a promising n...
PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases t...
Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunogenic safet...
With the reason that systemically administered adenovirus (Ad) is rapidly extinguished by innate/ada...
The targeting of gene transfer at the cell-entry level is one of the most attractive challenges in v...
ABSTRACT: Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunog...
The aim of this study was to change adenovirus tropism by chemical modification of the fiber knobs w...
Despite adenovirus (Ad) vector's numerous advantages for cancer gene therapy, such as high abili...
Due to the fundamental progress in elucidating the molecular mechanisms of human diseases and the ar...
Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intra...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
Tumour-associated vasculature provides an accessible target for systemic gene therapy using targeted...
PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases t...
Adenovirus (Ad) is a potential vehicle for cancer gene therapy. However, cells that express low leve...
Oncolytic adenoviruses (Ad) that selectively replicate in cancer cells are emerging as a promising n...
PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases t...
Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunogenic safet...
With the reason that systemically administered adenovirus (Ad) is rapidly extinguished by innate/ada...
The targeting of gene transfer at the cell-entry level is one of the most attractive challenges in v...
ABSTRACT: Adenovirus (Ad) vectors show promise as cancer gene therapy delivery vehicles, but immunog...